An analysis of registry data showed that patients with moderate-to-severe psoriasis treated with adalimumab had a 58% lower standardised mortality rate compared with the general population .
ESPRIT is an ongoing international, prospective, observational registry evaluating the long-term safety and effectiveness of the TNF blocker adalimumab in adults with moderate-to-severe chronic plaque psoriasis under real-world conditions. Ten-year data was analysed from 6,014 psoriasis patients with collectively 28,161 person-years on adalimumab in routine clinical practice.
“You may not believe it if someone tells you that you, as a dermatologist, can save patient lives by controlling psoriasis,” said Prof. Diamant Thaçi (University of Lübeck, Germany). Yet, this was exactly what the data showed: the standardised mortality ratio in participants in the ESPRIT registry was 58% lower than expected. A total of 144 deaths were predicted in the matched general population, yet only 60 deaths occurred in adalimumab-treated registry participants.
In addition, the incidence rates of serious infections, malignancies, and cardiovascular events in ESPRIT participants remained stable over time and well within the range of published rates in psoriasis patients not on biologic therapy. No new safety signals were observed and safety was consistent with the known safety profile of adalimumab.
As Prof. Thaçi pointed out, the positive mortality result is unexpected because the ESPRIT participants were typical for patients with moderate-to-severe psoriasis one usually encounters in clinical practice: many of them have cardiovascular risk factors, e.g. obesity and a substantial burden of comorbid conditions. The efficacy of adalimumab remained stable over the 10-year- period. “This result demonstrates the importance of good control of psoriasis,” concluded Prof. Thaçi.
- Thaçi D. FC01.02, EADV 2019, 9-13 Oct, Madrid, Spain.
« Anxiety and depression are common in families of AD infants Next Article
Systemic photoprotection: a valuable addition to topical sun protection »
Table of Contents: EADV 2019
Letter from the Editor
IL-17A blocker effective in paediatric psoriasis patients
Rituximab beats mycophenolate mofetil in pemphigus vulgaris
Novel JAK1/2 inhibitor shows remarkable efficacy in alopecia areata
Acne highly influenced by climate, pollutants, and unhealthy diet
JAK inhibition plus TCS lead to high clearance rates in AD
No cancer risk with long-term use of tacrolimus, a topical calcineurin inhibitor, in children with AD
Green light for a second JAK inhibitor in AD
Topical ruxolitinib effective in vitiligo
Small molecules: interesting novel treatment options in AD
IL-1⍺ blockade: a new treatment option in AD
IL-4/IL-13 blockade leads to rapid itch reduction in adolescents
How to manage conjunctivitis in AD patients treated with a biologic
Biologics: increasingly used in paediatric dermatology
Spotlight on Psoriasis
IL-17 blocker: effective and safe in patients with comorbidities
ESPRIT registry: sharp decline in mortality in patients treated with a TNF blocker
Relationship psoriasis and NAFLD: new data on the hepato-dermal axis
Novel selective IL-23 blocker equally effective in patients with metabolic syndrome
Selective IL-23 blocker crushes fumaric acids in all assessed efficacy endpoints
No hint of teratogenicity through ixekizumab
New Insights in Photoprotection
Systemic photoprotection: a valuable addition to topical sun protection
The underestimated effect of visible light
Comorbidities more common in chronic urticaria, psoriasis, and AD
D-Dimer as future biomarker in CSU management?
Ligelizumab for CSU: symptom control and high response rates in re-treatment
Rosacea – From New Spectrum to New Therapy
New guidance on rosacea therapy according to phenotype
Best of the Posters
Above-the-neck melanoma more prone to metastases
Reduced sleep quality in dermatoses influenced by itch and pain
Anxiety and depression are common in families of AD infants
Certolizumab pegol efficacious for head and neck psoriasis
ICD 2021 Highlights Podcast
Psoriasis associated with a higher cancer risk
Inhibition of heat shock protein: A novel way to treat psoriasis?